2023
Top advances of the year: Neuro‐oncology
Barden M, Omuro A. Top advances of the year: Neuro‐oncology. Cancer 2023, 129: 1467-1472. PMID: 36825454, DOI: 10.1002/cncr.34711.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBrain tumorsRecent phase 3 trialAnti-PD-1 immunotherapyCentral nervous system dysfunctionSingle-agent pembrolizumabHigh-dose chemotherapyPhase 3 trialPrimary CNS lymphomaStem cell transplantationLong-term outcomesLimited therapeutic optionsNervous system dysfunctionOngoing clinical trialsClinical trial landscapeDrug Administration approvalBRAF V600E mutationExcellent disease controlConsolidation therapyCNS lymphomaImproved survivalLeptomeningeal metastasesTherapeutic optionsCell transplantationCraniospinal irradiationPatient population
2019
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D’Angelo S, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics 2019, 51: 202-206. PMID: 30643254, PMCID: PMC6365097, DOI: 10.1038/s41588-018-0312-8.Peer-Reviewed Original ResearchConceptsTumor mutational burdenHigh tumor mutational burdenImproved survivalCancer typesImmune checkpoint inhibitor treatmentAdvanced cancer patientsBetter overall survivalCheckpoint inhibitor treatmentMultiple cancer typesClinical responseOverall survivalCancer patientsPredictive biomarkersCancer histologyMetastatic cancerMutational burdenPatientsInhibitor treatmentNext-generation sequencingSurvivalICIMutational loadUniversal definitionAssociationImmunotherapy
2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreElderly PCNSL patientsFirst-line therapyHD-MTXIndividual patient dataPCNSL patientsImproved survivalEligible studiesElderly primary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaSystematic reviewCentral nervous system lymphomaHigh-dose methotrexatePatient dataWhole brain radiotherapyFirst-line treatmentNervous system lymphomaStrong prognostic factorElderly patientsImmunocompetent patientsProspective trialMedian ageOral chemotherapyPrognostic factors
2008
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, investigators O. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). European Journal Of Cancer 2008, 44: 1210-1216. PMID: 18248979, DOI: 10.1016/j.ejca.2007.12.005.Peer-Reviewed Original ResearchConceptsProgression-free survivalCentral pathology reviewOverall survivalAnaplastic astrocytomaMonths 95Pathology reviewAA patientsGlioblastoma multiformeConfidence intervalsPrevious phase III trialsMedian overall survivalPhase III studyPhase III trialsGrade 3 tumorsLonger overall survivalTotal treatment durationAdjuvant chemotherapyEORTC studyAdjuvant regimenIII studyIII trialsImproved survivalTreat analysisPathological assessmentBCNU chemotherapy
2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. JAMA Neurology 2005, 62: 1595-1600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.Peer-Reviewed Original ResearchConceptsPrimary central nervous lymphomaPathophysiologic mechanismsPrimary central nervous system lymphomaMemorial Sloan-Kettering Cancer CenterTreatment-related toxic effectsCentral nervous system lymphomaDiffuse white matter diseaseAvailable autopsy dataProgressive subcortical dementiaMental status changesNervous system lymphomaDepartment of NeurologyWhite matter damagePotential risk factorsWhite matter diseaseFrontal-subcortical circuitsMicrovascular alterationsNeurologic deteriorationCumulative incidenceClinical courseImproved survivalRetrospective reviewSystem lymphomaClinical findingsSubcortical dementia